Core Viewpoint - SS&C Technologies (SSNC) has experienced significant selling pressure, resulting in a 16% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential rebound for the stock [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if SSNC is oversold, with a current RSI reading of 28.14, suggesting that the stock may soon reverse its downward trend [2][5]. - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify potential price reversals, indicating that SSNC may present an entry opportunity for investors [3]. Group 2: Fundamental Indicators - Analysts have raised earnings estimates for SSNC by 2.7% over the last 30 days, reflecting a strong consensus among sell-side analysts, which typically correlates with price appreciation in the near term [7]. - SSNC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround in the stock's performance [8].

Expedia (EXPE) has been on a downward spiral lately with significant selling pressure. After declining 25.4% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillat ...

For the quarter ended December 2025, Somnigroup International (SGI) reported revenue of $1.87 billion, up 54.7% over the same period last year. EPS came in at $0.72, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of -3.24% over the Zacks Consensus Estimate of $1.93 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +0.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Cardinal Health (CAH) .Cardinal currently has an average brokerage recomme ...

Core Insights - Medtronic reported $9.02 billion in revenue for the quarter ended January 2026, marking an 8.7% year-over-year increase and a surprise of +1.35% over the Zacks Consensus Estimate of $8.9 billion [1] - The earnings per share (EPS) for the same period was $1.36, slightly down from $1.39 a year ago, with an EPS surprise of +2.07% compared to the consensus estimate of $1.33 [1] Revenue Breakdown - U.S. Revenue: $4.49 billion, a 6% year-over-year increase, but below the average estimate of $4.59 billion [4] - International Revenue: $4.52 billion, exceeding the average estimate of $4.3 billion [4] - Cardiovascular Revenue: $3.46 billion, a 13.8% year-over-year increase, surpassing the average estimate of $3.39 billion [4] - Neuroscience Revenue: $2.56 billion, a 4.1% year-over-year increase, slightly below the average estimate of $2.58 billion [4] - Medical Surgical Revenue: $2.17 billion, a 4.9% year-over-year increase, exceeding the average estimate of $2.14 billion [4] - Diabetes Revenue: $796 million, a 14.7% year-over-year increase, surpassing the average estimate of $773.73 million [4] - Cardiac Rhythm & Heart Failure Revenue: $1.86 billion, a significant 20.1% year-over-year increase, exceeding the average estimate of $1.8 billion [4] Stock Performance - Medtronic shares have returned +2.8% over the past month, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - Labcorp Holdings reported revenue of $3.52 billion for the quarter ended December 2025, reflecting a 5.6% increase year-over-year [1] - The company's EPS for the quarter was $4.07, up from $3.45 in the same quarter last year, with an EPS surprise of +2.98% compared to the consensus estimate of $3.95 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $3.55 billion, resulting in a revenue surprise of -0.97% [1] Group 2 - Key metrics indicate that Labcorp's shares have returned +4.3% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Group 3 - The net book-to-bill ratio for Labcorp was reported at 1.1%, matching the average estimate based on two analysts [4] - Revenues from Biopharma Laboratory Services were $793 million, slightly above the average estimate of $791.05 million, representing a year-over-year change of +3.4% [4] - Revenues from Diagnostics Laboratories were $2.73 billion, below the average estimate of $2.77 billion, with a year-over-year change of +5.5% [4] - Adjusted Operating Income for Diagnostics Laboratories was $419.2 million, slightly below the average estimate of $423.58 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $136.1 million, exceeding the average estimate of $130.1 million [4] - Unallocated corporate expenses were reported at -$67.6 million, better than the average estimate of -$69.13 million [4]

Leidos (LDOS) reported $4.21 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 3.6%. EPS of $2.76 for the same period compares to $2.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $4.25 billion, representing a surprise of -1.07%. The company delivered an EPS surprise of +7.6%, with the consensus EPS estimate being $2.57.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Core Viewpoint - Extra Space Storage (EXR) is expected to report a year-over-year revenue increase in its fourth-quarter 2025 results, with no change in funds from operations (FFO) per share [1][10]. Financial Performance - In the last reported quarter, EXR achieved an FFO per share of $2.08, exceeding the Zacks Consensus Estimate of $2.06, driven by increased revenues from higher occupancy [2]. - The Zacks Consensus Estimate for quarterly property rental revenues is $731.87 million, up from $707.23 million in the same period last year [4]. - The estimate for revenues from tenant insurance is projected at $88.44 million, an increase from $83.70 million year-over-year [4]. - Management fees and other income are expected to rise to $32.09 million from $30.97 million in the previous year [4]. - Overall, the Zacks Consensus Estimate for total quarterly revenues stands at $864.48 million, indicating a 5.18% year-over-year growth [5][10]. Market Position and Challenges - EXR operates in a fragmented market with significant competition, facing challenges from price-sensitive customers and lower new customer rates, which may impact earnings [5][10]. - The self-storage industry is characterized as need-based and resilient to economic downturns, benefiting from favorable demographic trends [3]. Analyst Sentiment - Over the past four quarters, EXR has beaten the Zacks Consensus Estimate three times, with an average surprise of 0.76% [3]. - However, the consensus estimate for core FFO per share has decreased to $2.03, indicating no change from the previous year [6]. - The current Earnings ESP for EXR is -1.61%, and it holds a Zacks Rank of 4 (Sell), suggesting limited potential for a positive earnings surprise this quarter [8].

Key Takeaways HSIC is set to report Q4 2025 results on Feb. 24, with revenues projected to rise 4.5% year over year.Henry Schein's Global Specialty Products revenues are expected to grow 5.9% on implant strength.HSIC's Global Technology sales are projected to jump 9.7% on SaaS and cloud momentum.Henry Schein, Inc. (HSIC) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which su ...

Core Insights - Hormel Foods Corporation (HRL) enters fiscal 2026 with improved earnings visibility after a challenging fiscal 2025, expecting transitional headwinds early in the year but anticipating better performance as cost actions and pricing benefits take effect [1][5] Earnings Outlook - Near-term visibility is limited, with management forecasting a year-over-year decline in first-quarter earnings due to delayed pricing actions, ongoing supply constraints from avian influenza, and timing issues with administrative cost savings [2] - Beyond the first quarter, earnings visibility is expected to improve significantly, with guidance for adjusted earnings per share of $1.43 to $1.51 for fiscal 2026, indicating a growth of 4% to 10% [3][8] - The earnings framework is supported by the full-year benefits of pricing actions from fiscal 2025, productivity gains from the Transform and Modernize initiative, and savings from a corporate restructuring program aimed at reducing administrative expenses [4] Market Conditions - The company anticipates a pressured consumer environment and elevated input costs, particularly for beef, but expects the impact of pricing realization, cost control measures, and operational efficiency initiatives to support fiscal 2026 earnings [5] - Hormel Foods' shares have decreased by 1.8% over the past month, underperforming the broader Consumer Staples sector, which grew by 9.8%, while still outperforming the S&P 500 index's decline of 1.9% [6] Valuation - Hormel Foods currently trades at a forward 12-month P/E ratio of 15.94, which is higher than the industry average of 13.18, indicating market expectations regarding its business stability and ability to manage current cost and demand dynamics [10]